Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 14/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.49 |
| ▸ | PLG | P00747 | 9/20 | 0.47 |
| ▸ | F2 | P00734 | 8/20 | 0.47 |
| ▸ | PLAT | P00750 | 8/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.47 |
| ▸ | KLK1 | P06870 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431376 | 0.90 | PLAU (0.66) | PLAUPLGF2PLATKLKB1 | |
| SCHEMBL5430957 | 0.83 | PLAU (0.59) | PLAUPLGF2PLATKLKB1 | |
| SCHEMBL1626717 | 0.83 | ALDH1A1 (0.57) | — | |
| Hydrochloric Acid SCHEMBL8700251 | 0.82 | PLAU (0.58) | PLAUPLGF2PLATKLKB1 | |
| Guanidine SCHEMBL27709689 | 0.82 | PLAU (0.58) | PLAUPLGF2PLATKLKB1 | |
| SCHEMBL30071591 | 0.81 | PLAU (0.57) | PLAUPLGF2PLATF10 | |
| SCHEMBL5440163 | 0.81 | PLAU (0.57) | PLAUPLGF2PLATF10 | |
| SCHEMBL16302072 | 0.81 | PLAU (0.64) | PLAUCYP2A6CYP1A2 | |
| SCHEMBL5431020 | 0.81 | PLAU (0.55) | PLAUPLGF2PLATKLKB1 | |
| SCHEMBL18951239 | 0.80 | CYP2A6 (0.55) | PLAUCYP2A6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376231-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2016-12-29 | — | — | US | claimed |
| US-20100254942-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LIMITED (AU) | 2010-10-07 | — | — | US | claimed |
| CN-101827589-A | Hepatitis c antiviral compositions and methods | BIOTROM LTD | 2010-09-08 | — | — | CN | claimed |
| EP-2194976-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | Biotron Limited (AU) | 2010-06-16 | — | — | EP | claimed |
| US-20090099239-A1 | Antiviral Compounds and Methods | BIOTRON LIMITED (AU) | 2009-04-16 | — | — | US | claimed |
| WO-2009018609-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTROM LIMITED (AU) | 2009-02-12 | — | — | WO | claimed |
| JP-2008543886-A | — | — | 2008-12-04 | — | — | JP | claimed |
| EP-1902017-A1 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2008-03-26 | — | — | EP | claimed |
| WO-2006135978-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2006-12-28 | — | — | WO | claimed |
| US-20200385340-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LTD (AU) | 2020-12-10 | — | — | US | disclosed |
| US-10683263-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2020-06-16 | — | — | US | disclosed |
| US-10683263-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2020-06-16 | — | — | US | disclosed |
| EP-2826770-B1 | ACYLGUANIDINE COMPOUNDS WITH ANTIVIRAL ACTIVITY | BIOTRON LTD (AU) | 2018-09-12 | — | — | EP | disclosed |
| US-20170362170-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LTD (AU) | 2017-12-21 | — | — | US | disclosed |
| US-20090099239-A1 | Antiviral Compounds and Methods | BIOTRON LIMITED (AU) | 2009-04-16 | — | — | US | disclosed |
| WO-2009018609-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTROM LIMITED (AU) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009018609-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTROM LIMITED (AU) | 2009-02-12 | — | — | WO | disclosed |
| CN-101208297-A | Antiviral compounds and methods | BIOTRON LTD (AU) | 2008-06-25 | — | — | CN | disclosed |
| EP-1902017-A1 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006135978-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254942-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | PLAU 1068/4885CYP2A6 2509/4885PLG 2771/4885 |
| US-10683263-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | PLAU 2188/4885CYP2A6 2623/4885PLG 3576/4885 |
| US-20170362170-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | PLAU 1068/4885CYP2A6 2509/4885PLG 2771/4885 |
| US-20090099239-A1 | Antiviral Compounds and Methods | MAVS, ZC3HAV1, EIF2AK2 | PLAU 2188/4885CYP2A6 2623/4885PLG 3576/4885 |
| US-20160376231-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | PLAU 2188/4885CYP2A6 2623/4885PLG 3576/4885 |
| US-20200385340-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | PLAU 1068/4885CYP2A6 2509/4885PLG 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.